Rethinking antipsychotic formulary policy

Schizophrenia Bulletin

Volumn 34, Issue 2, 2008, Pages 375-380

  Rosenheck, R A ^a,b   Leslie, D L ^a,b   Busch, Susan ^a   Rofman, Ethan S ^c,d   Sernyak, Michael ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c VA New England Health Care System   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic medication; Public policy; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LOXAPINE SUCCINATE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TIOTIXENE; ZIPRASIDONE;

AGRANULOCYTOSIS; ALGORITHM; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE POLICY; HUMAN; METABOLIC SYNDROME X; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; HEALTH POLICY; HUMANS; MENTAL HEALTH SERVICES; PUBLIC POLICY; SCHIZOPHRENIA;

EID: 40049105385     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm089     Document Type: Article

References (57)

1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
2. Tollefson GD, Beasley CMJr, Tran PV. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.
3. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425.
4. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65:500-508.
5. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. 2nd edition. Washington, DC American Psychiatric Association; 2004, p. 16.
6. Leslie D, Rosenheck RA. Sixth Annual Report on Pharmacotheroy of Schizophrenia in the Department of Veterans Affairs. West Haven, CT: Northeast Program Evaluation Center; 2006.
7. Vital Signs. Clin Psychiatr News. 2007;35:1.
8. Scully JH, Wilk JE. Selected characteristics and data of psychiatrists in the US, 2001-2002. Acad Psychiatry. 2003;27:247-251.
9. US Department of Labor, Bureau of Labor Statistics Occupational Outlook Handbook. http://www.bls.gov/oco/ocos074.htm (accessed May 2,2007).
10. Mark TL, Coffey RM, Vandivort-Warren R, Harwood HJ, King EC. MHSA Spending Estimates Team. U.S. spending for mental health and substance abuse treatment, 1991-2001. Health Affairs. Suppl Web Exclusives. 2005;W5-133-W5-142.
11. Kaiser Family Foundation Health Care Spending in the United States and OECD Countries: January 2007 Accessed on February 7, 2007 at http://www.kff.org/insurance/snapshot/chcm010307oth.cfm.
12. Schoen C, Davis C, How SKH, Schoenbaum SC. U.S. Health System Performance: A National Scorecard Health Affairs, November/December. 2006;25(6):w457-w475.
13. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews: Reviews 2005 Issue 2. John Wiley & Sons, Ltd Chichester, UK. Available at: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001359/frame. html. Accessed on June 6, 2007.
14. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews: Reviews 2003 Issue 2. John Wiley & Sons, Ltd Chichester, UK. Available at: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/ articles/CD000440/frame.html. Accessed on June 6, 2007.
15. Rosenheck RA, Perlick D, Bingham S, Liu-Mares, Collins J, Warren S, Leslie D. for the Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA. 2003;290:2693-2702.
16. Lieberman JA, Stroup S, McEvoy J, et al. for the CATIE Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. N Engl J Med. 2005;353:1209-1223.
17. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of effect on quality of life of second generation versus first generation antipsychotic drugs in schizophrenia - CUtLASS1. Arch Gen Psychiatry. 2006;63:1079-1087.
18. Rosenheck RA, Leslie D, Sindelar J, et al. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163:2080-2089.
19. Rosenheck RA, Doyle J, Leslie D, Fontana A. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Schizophr Bull. 2003;29:81-93.
20. Swartz M, Perkins D, Stroup S, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE Study. Am J Psychiatry. 2007;164:428-436.
21. Meltzer HY, Bobo WV. Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectr 11. 2006;(suppl 7):14-24.
22. Kane JM. Commentary on the Clinical Antipsychotic Trials of Intervnetion Effectivenenss (CATIE). J Clin Psychiatry. 2006;76:831-832.
23. Tandon R, Constatine R. Avoiding EPS is key to realizing "atypical benefits". Curr Psychiatry. 2006;5:35-45.
24. Rosenheck RA, Swartz M, McEvoy J, et al. Changing perspectives on second generation antipsychotics: reviewing the cost-effectiveness component of the CATIE Trial. Expert Rev Pharmacoeconomics Outcomes Research. 2007;7(2):103-111.
25. Constatine RJ, Tandon R. Antipsychotics equivalent? CUtLASS renews the debate. Curr Psychiatry. 2007;6:58-68,78.
26. Lieberman JA, Tollefson G, Tohen M, et al. HGDH Study Group.Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396-1404.
27. Schooler N, Rabinowitz J, Davidson M, et al. Early Psychosis Global Working Group..Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162:947-953.
28. Rummel C, Hamann J, Kissling W, Leucht S. New Generation Antipsychotics for First Episode Schizophrenia. Cochrane Database of Systematic Reviews: Reviews 2003 Issue 4 John Wiley & Sons, Ltd Chichester, UK Available at: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004410/frame. html. Accessed June 7, 2007.
29. Marder SR. Lessons from each drug trial. Am J Psychiatry. 2007;164:375-376.
30. Polsky D, Doshi JA, Bauer MS, Glick HA. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry. 2006;163:2047-2056.
31. US General Accounting Office. VA Health Care: Implementation of Prescribing Guideline for Atypical Antipsychotic Drugs Generally Sound. Washington, DC: GAO; 2002:502-579.
32. Rosenheck RA, Leslie DL, Sernyak ME. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Med Care. 2001;39:302-308.
33. Agency for Health Care Research and Quality. Comparative Effectiveness Review No. 6 Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics. Available at: http://effectivehealthcare.ahrq.gov/repFiles/ Atypical_Antipsychotics_Final_Report.pdf. Accessed on May 19, 2007.
34. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why Olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163:185-194.
35. Montgomery JH, Byerly M, Carmody T, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials. 2004;25:598-612.
36. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-465.
37. Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ. 2006;333:782.
38. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167-1170.
39. Rosack J. Experts say tread slowly when trying to interpret study results. Psychiatr News. 2006;41:23.
40. American Diabetes Association (ADA) American Psychiatric Association American Association of Clinical endocrinologists North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
41. Sernyak MJ, Leslie D, Alarcon R, Losonczy M, Rosenheck RA. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566.
42. Leslie D, Rosenheck RA. Incidence of new-onset diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161:1709-1711.
43. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581-1589.
44. Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale Schizophrenia Surveys 23: movement disorders. Br J Psychiatry. 2002;181:422-427.
45. Rochon PA, Stukel TA, Sykora K, et al. Atypical Antipsychotics and Parkinsonism. Arch Intern Med. 2005;165:1882-1888.
46. Lee PE, Sykora K, Gill SS, et al. Antipsychotic medication and drug-induced movement disorder: A population-based cohort study in older adults. J Am Geriatr Soc. 2005;53:1374-1379.
47. Tamminga C. Clinical course and cellular pathology of tardive dyskinesia. In: Davis KL, Charney DS, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress Baltimore, MD: Lippincott Williams & Wilkins; 2002.
48. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry. 1994;55:suppl B:102-106.
49. Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Progress in NeuroPsychopharmacol Biol Psychiatry. 2004;28:985-996.
50. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999;47:716-719.
51. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157:1150-1155.
52. Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R. for the Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;68:213-223.
53. Stroup TS, Lieberman JA, McEvoy JP, et al. for the CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611-622.
54. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication in the treatment of schizophrenia. Psychiatr Serv. 2003;54:508-516.
55. Essock SM, Covell NH, Davis SM, Stroup SS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163:2090-2095.
56. Daniels N, Sabin J. Setting Limits Fairly: Can We Learn to Share Medical Resources? New York, NY.: Oxford; 2003.
57. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach: a randomized controlled trial of academically based "detailing. N Engl J Med. 1983;308:1457-1463.